These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8889080)

  • 81. The differentiation between 'lack of insight' and 'dysfunctional health beliefs' in schizophrenia.
    Linden M; Godemann F
    Psychopathology; 2007; 40(4):236-41. PubMed ID: 17396050
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Control beliefs, therapeutic relationship, and adherence in schizophrenia outpatients: a cross-sectional study.
    Jaeger S; Weißhaupt S; Flammer E; Steinert T
    Am J Health Behav; 2014 Nov; 38(6):914-23. PubMed ID: 25207516
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings.
    Kampman O; Lehtinen K; Lassila V
    Acta Psychiatr Scand; 2001 Oct; 104(4):299-304. PubMed ID: 11722305
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis.
    Heres S; Hamann J; Mendel R; Wickelmaier F; Pajonk FG; Leucht S; Kissling W
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1987-93. PubMed ID: 18948163
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Insight in schizophrenia. Its relationship to acute psychopathology.
    McEvoy JP; Apperson LJ; Appelbaum PS; Ortlip P; Brecosky J; Hammill K; Geller JL; Roth L
    J Nerv Ment Dis; 1989 Jan; 177(1):43-7. PubMed ID: 2562850
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1993 Apr; 38(3):159-61. PubMed ID: 8098988
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [The (new) definition of compliance].
    Arolt V
    Krankenpfl J; 2005; 43(7-10):214-5. PubMed ID: 16515287
    [No Abstract]   [Full Text] [Related]  

  • 92. Teaching medication management skills to schizophrenic patients.
    Eckman TA; Liberman RP; Phipps CC; Blair KE
    J Clin Psychopharmacol; 1990 Feb; 10(1):33-8. PubMed ID: 1968471
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Characteristics of clients with schizophrenia who express certainty or uncertainty about continuing treatment with depot neuroleptic medication.
    Bunn MH; O'Connor AM; Tansey MS; Jones BD; Stinson LE
    Arch Psychiatr Nurs; 1997 Oct; 11(5):238-48. PubMed ID: 9336992
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Compliance and psychological reactance in schizophrenia.
    Moore A; Sellwood W; Stirling J
    Br J Clin Psychol; 2000 Sep; 39(3):287-95. PubMed ID: 11033750
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Insight and moderating variables.
    Kingsbury SJ; Yi D
    Psychiatr Serv; 2001 Mar; 52(3):387-8. PubMed ID: 11239115
    [No Abstract]   [Full Text] [Related]  

  • 96. Reducing recidivism: medication versus psychosocial rehabilitation.
    Delaney C
    J Psychosoc Nurs Ment Health Serv; 1998 Nov; 36(11):28-34. PubMed ID: 9822993
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Benefits of Staying on Medication.
    Jepson JA
    Schizophr Bull; 2021 Jan; 47(1):4. PubMed ID: 31603513
    [No Abstract]   [Full Text] [Related]  

  • 98. Medication compliance among the seriously mentally ill in a public mental health system.
    Nageotte C; Sullivan G; Duan N; Camp PL
    Soc Psychiatry Psychiatr Epidemiol; 1997 Feb; 32(2):49-56. PubMed ID: 9050344
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Tool development for profiling the attitude of clients with schizophrenia toward their medication, using Fishbein's expectancy-value model.
    Davidhizar RE
    Issues Ment Health Nurs; 1982; 4(4):343-57. PubMed ID: 6927620
    [No Abstract]   [Full Text] [Related]  

  • 100. What can we achieve by implementing a compliance-improvement program?
    Kane JM
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S43-6. PubMed ID: 9179643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.